Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Nov;24(64):1–128. doi: 10.3310/hta24640

Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT.

Jonathan M Batchelor, Kim S Thomas, Perways Akram, Jaskiran Azad, Anthony Bewley, Joanne R Chalmers, Seau Tak Cheung, Lelia Duley, Viktoria Eleftheriadou, Robert Ellis, Adam Ferguson, Jonathan Mr Goulding, Rachel H Haines, Hamdi Hamad, John R Ingram, Bisola Laguda, Paul Leighton, Nick Levell, Areti Makrygeorgou, Garry D Meakin, Adam Millington, Malobi Ogboli, Amirtha Rajasekaran, Jane C Ravenscroft, Andrew Rogers, Tracey H Sach, Miriam Santer, Julia Stainforth, Wei Tan, Shyamal Wahie, Jennifer White, Maxine E Whitton, Hywel C Williams, Andrew Wright, Alan A Montgomery
PMCID: PMC7750863  PMID: 33245043

Abstract

BACKGROUND

Systematic reviews suggest that narrowband ultraviolet B light combined with treatments such as topical corticosteroids may be more effective than monotherapy for vitiligo.

OBJECTIVE

To explore the clinical effectiveness and cost-effectiveness of topical corticosteroid monotherapy compared with (1) hand-held narrowband ultraviolet B light monotherapy and (2) hand-held narrowband ultraviolet B light/topical corticosteroid combination treatment for localised vitiligo.

DESIGN

Pragmatic, three-arm, randomised controlled trial with 9 months of treatment and a 12-month follow-up.

SETTING

Sixteen UK hospitals - participants were recruited from primary and secondary care and the community.

PARTICIPANTS

Adults and children (aged ≥ 5 years) with active non-segmental vitiligo affecting ≤ 10% of their body area.

INTERVENTIONS

Topical corticosteroids [mometasone furoate 0.1% (Elocon®, Merck Sharp & Dohme Corp., Merck & Co., Inc., Whitehouse Station, NJ, USA) plus dummy narrowband ultraviolet B light]; narrowband ultraviolet B light (narrowband ultraviolet B light plus placebo topical corticosteroids); or combination (topical corticosteroids plus narrowband ultraviolet B light). Topical corticosteroids were applied once daily on alternate weeks and narrowband ultraviolet B light was administered every other day in escalating doses, with a dose adjustment for erythema. All treatments were home based.

MAIN OUTCOME MEASURES

The primary outcome was self-assessed treatment success for a chosen target patch after 9 months of treatment ('a lot less noticeable' or 'no longer noticeable' on the Vitiligo Noticeability Scale). Secondary outcomes included blinded assessment of primary outcome and percentage repigmentation, onset and maintenance of treatment response, quality of life, side effects, treatment burden and cost-effectiveness (cost per additional successful treatment).

RESULTS

In total, 517 participants were randomised (adults, n = 398; and children, n =  119; 52% male; 57% paler skin types I-III, 43% darker skin types IV-VI). At the end of 9 months of treatment, 370 (72%) participants provided primary outcome data. The median percentage of narrowband ultraviolet B light treatment-days (actual/allocated) was 81% for topical corticosteroids, 77% for narrowband ultraviolet B light and 74% for combination groups; and for ointment was 79% for topical corticosteroids, 83% for narrowband ultraviolet B light and 77% for combination. Target patch location was head and neck (31%), hands and feet (32%), and rest of the body (37%). Target patch treatment 'success' was 20 out of 119 (17%) for topical corticosteroids, 27 out of 123 (22%) for narrowband ultraviolet B light and 34 out of 128 (27%) for combination. Combination treatment was superior to topical corticosteroids (adjusted risk difference 10.9%, 95% confidence interval 1.0% to 20.9%; p = 0.032; number needed to treat = 10). Narrowband ultraviolet B light was not superior to topical corticosteroids (adjusted risk difference 5.2%, 95% confidence interval -4.4% to 14.9%; p = 0.290; number needed to treat = 19). The secondary outcomes supported the primary analysis. Quality of life did not differ between the groups. Participants who adhered to the interventions for > 75% of the expected treatment protocol were more likely to achieve treatment success. Over 40% of participants had lost treatment response after 1 year with no treatment. Grade 3 or 4 erythema was experienced by 62 participants (12%) (three of whom were using the dummy) and transient skin thinning by 13 participants (2.5%) (two of whom were using the placebo). We observed no serious adverse treatment effects. For combination treatment compared with topical corticosteroids, the unadjusted incremental cost-effectiveness ratio was £2328.56 (adjusted £1932) per additional successful treatment (from an NHS perspective).

LIMITATIONS

Relatively high loss to follow-up limits the interpretation of the trial findings, especially during the post-intervention follow-up phase.

CONCLUSION

Hand-held narrowband ultraviolet B light plus topical corticosteroid combination treatment is superior to topical corticosteroids alone for treatment of localised vitiligo. Combination treatment was relatively safe and well tolerated, but was effective in around one-quarter of participants only. Whether or not combination treatment is cost-effective depends on how much decision-makers are willing to pay for the benefits observed.

FUTURE WORK

Development and testing of new vitiligo treatments with a greater treatment response and longer-lasting effects are needed.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN17160087.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 64. See the NIHR Journals Library website for further project information.

Plain language summary

The Home Interventions and Light therapy for the treatment of vitiligo (HI-Light Vitiligo) trial aimed to find out whether or not treating vitiligo at home with a narrowband ultraviolet B light, either by itself or with a steroid ointment, is better than treatment using a steroid ointment only. We enrolled 517 children (aged ≥ 5 years) and adults who had small, active (i.e. recently changing) patches of vitiligo into the study. Participants received one of three possible treatment options: steroid ointment (plus dummy light), hand-held narrowband ultraviolet B light therapy (plus placebo ointment) or both treatments used together. We asked participants to judge how noticeable their target vitiligo patch was after 9 months of treatment. We considered the treatment to be successful if the participants’ responses were either ‘a lot less noticeable’ or ‘no longer noticeable’. The results showed that using both treatments together was better than using a steroid ointment on its own. Around one-quarter of participants (27%) who used both treatments together said that their vitiligo was either ‘no longer noticeable’ or ‘a lot less noticeable’ after 9 months of treatment. This was compared with 17% of those using steroid ointment on its own and 22% of those using narrowband ultraviolet B light on its own. All treatments were able to stop the vitiligo from spreading. Patches on the hands and feet were less likely to respond to treatment than patches on other parts of the body. The trial found that the vitiligo tended to return once treatments were stopped, so ongoing intermittent treatment may be needed to maintain the treatment response. The treatments were found to be relatively safe and easy to use, but light treatment required a considerable time commitment (approximately 20 minutes per session, two or three times per week). This trial showed that using steroid ointment and narrowband ultraviolet B light together is likely to be better than steroid ointment alone for people with small patches of vitiligo. Steroid ointment alone can still be effective for some people and remains a useful treatment that is able to stop vitiligo from spreading. The challenge is to make hand-held narrowband ultraviolet B light treatment available as normal care in the NHS for people with vitiligo.

Full text of this article can be found in Bookshelf.

References

  1. Dell’anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006;19:406–11. https://doi.org/10.1111/j.1600-0749.2006.00333.x doi: 10.1111/j.1600-0749.2006.00333.x. [DOI] [PubMed]
  2. Denman CJ, McCracken J, Hariharan V, Klarquist J, Oyarbide-Valencia K, Guevara-Patiño JA, Le Poole IC. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J Invest Dermatol 2008;128:2041–8. https://doi.org/10.1038/jid.2008.45 doi: 10.1038/jid.2008.45. [DOI] [PMC free article] [PubMed]
  3. Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993;2:145–53. https://doi.org/10.1111/j.1600-0625.1993.tb00023.x doi: 10.1111/j.1600-0625.1993.tb00023.x. [DOI] [PubMed]
  4. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, Nickoloff BJ, Das PK. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004;9:68–72. https://doi.org/10.1111/j.1087-0024.2004.00825.x doi: 10.1111/j.1087-0024.2004.00825.x. [DOI] [PubMed]
  5. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elassiuty YE, Kemp EH, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008;17:139–40. https://doi.org/10.1111/j.1600-0625.2007.00666_1.x doi: 10.1111/j.1600-0625.2007.00666_1.x. [DOI] [PubMed]
  6. Taïeb A. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res 2000;13(Suppl. 8):41–7. https://doi.org/10.1034/j.1600-0749.13.s8.9.x doi: 10.1034/j.1600-0749.13.s8.9.x. [DOI] [PubMed]
  7. Spritz RA. The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma. Genome Med 2010;2:78. https://doi.org/10.1186/gm199 doi: 10.1186/gm199. [DOI] [PMC free article] [PubMed]
  8. Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 1977;113:47–52. https://doi.org/10.1001/archderm.113.1.47 doi: 10.1001/archderm.113.1.47. [DOI] [PubMed]
  9. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149–56. https://doi.org/10.4103/0378-6323.32708 doi: 10.4103/0378-6323.32708. [DOI] [PubMed]
  10. Singh M, Singh G, Kanwar AJ, Belhaj MS. Clinical pattern of vitiligo in Libya. Int J Dermatol 1985;24:233–5. https://doi.org/10.1111/j.1365-4362.1985.tb05445.x doi: 10.1111/j.1365-4362.1985.tb05445.x. [DOI] [PubMed]
  11. Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B. Studies on vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 1985;2:71–8. https://doi.org/10.1002/gepi.1370020107 doi: 10.1002/gepi.1370020107. [DOI] [PubMed]
  12. Zhang Y, Cai Y, Shi M, Jiang S, Cui S, Wu Y, et al. The prevalence of vitiligo: a meta-analysis. PLOS ONE 2016;11:e0163806. https://doi.org/10.1371/journal.pone.0163806 doi: 10.1371/journal.pone.0163806. [DOI] [PMC free article] [PubMed]
  13. Fitzpatrick TB. Hypomelanosis. South Med J 1964;57:995–1005. https://doi.org/10.1097/00007611-196409000-00001 doi: 10.1097/00007611-196409000-00001. [DOI] [PubMed]
  14. Hann SK, Park YK, Chun WH. Clinical features of vitiligo. Clin Dermatol 1997;15:891–7. https://doi.org/10.1016/S0738-081X(97)00130-2 doi: 10.1016/S0738-081X(97)00130-2. [DOI] [PubMed]
  15. Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry 1979;1:73–7. https://doi.org/10.1016/0163-8343(79)90081-1 doi: 10.1016/0163-8343(79)90081-1. [DOI] [PubMed]
  16. Ezzedine K, Grimes PE, Meurant JM, Seneschal J, Léauté-Labrèze C, Ballanger F, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol 2015;173:607–9. https://doi.org/10.1111/bjd.13839 doi: 10.1111/bjd.13839. [DOI] [PubMed]
  17. Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol 2017;177:708–18. https://doi.org/10.1111/bjd.15199 doi: 10.1111/bjd.15199. [DOI] [PubMed]
  18. Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, et al. Vitiligo is not a cosmetic disease. J Am Acad Dermatol 2015;73:883–5. https://doi.org/10.1016/j.jaad.2015.07.039 doi: 10.1016/j.jaad.2015.07.039. [DOI] [PubMed]
  19. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008;159:1051–76. https://doi.org/10.1111/j.1365-2133.2008.08881.x doi: 10.1111/j.1365-2133.2008.08881.x. [DOI] [PubMed]
  20. Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013;168:5–19. https://doi.org/10.1111/j.1365-2133.2012.11197.x doi: 10.1111/j.1365-2133.2012.11197.x. [DOI] [PubMed]
  21. Eleftheriadou V, Whitton ME, Gawkrodger DJ, Batchelor J, Corne J, Lamb B, et al. Future research into the treatment of vitiligo: where should our priorities lie? Results of the vitiligo priority setting partnership. Br J Dermatol 2011;164:530–6. https://doi.org/10.1111/j.1365-2133.2010.10160.x doi: 10.1111/j.1365-2133.2010.10160.x. [DOI] [PMC free article] [PubMed]
  22. Whitton ME, Pinart M, Batchelor J, Lushey C, Leonardi-Bee J, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev 2010;1:CD003263. https://doi.org/10.1002/14651858.CD003263.pub4 doi: 10.1002/14651858.CD003263.pub4. [DOI] [PubMed]
  23. Madigan LM, Al-Jamal M, Hamzavi I. Exploring the gaps in the evidence-based application of narrowband UVB for the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2016;32:66–80. https://doi.org/10.1111/phpp.12228 doi: 10.1111/phpp.12228. [DOI] [PubMed]
  24. Eleftheriadou V, Thomas K, Ravenscroft J, Whitton M, Batchelor J, Williams H. Feasibility, double-blind, randomised, placebo-controlled, multi-centre trial of hand-held NB-UVB phototherapy for the treatment of vitiligo at home (HI-Light trial: Home Intervention of Light therapy). Trials 2014;15:51. https://doi.org/10.1186/1745-6215-15-51 doi: 10.1186/1745-6215-15-51. [DOI] [PMC free article] [PubMed]
  25. Dong DK, Pan ZY, Zhang J, Lu XF, Jin C, Tao SQ, Yang LJ. Efficacy and safety of targeted high-intensity medium-band (304-312 nm) ultraviolet B light in pediatric vitiligo. Pediatr Dermatol 2017;34:266–70. https://doi.org/10.1111/pde.13098 doi: 10.1111/pde.13098. [DOI] [PubMed]
  26. Tien Guan ST, Theng C, Chang A. Randomized, parallel group trial comparing home-based phototherapy with institution-based 308 excimer lamp for the treatment of focal vitiligo vulgaris. J Am Acad Dermatol 2015;72:733–5. https://doi.org/10.1016/j.jaad.2014.12.026 doi: 10.1016/j.jaad.2014.12.026. [DOI] [PubMed]
  27. Cameron H, Yule S, Dawe RS, Ibbotson SH, Moseley H, Ferguson J. Review of an established UK home phototherapy service 1998–2011: improving access to a cost-effective treatment for chronic skin disease. Public Health 2014;128:317–24. https://doi.org/10.1016/j.puhe.2014.01.011 doi: 10.1016/j.puhe.2014.01.011. [DOI] [PubMed]
  28. Nolan BV, Yentzer BA, Feldman SR. A review of home phototherapy for psoriasis. Dermatol Online J 2010;16:1. [PubMed]
  29. Wind BS, Kroon MW, Beek JF, van der Veen JP, Nieuweboer-Krobotová L, Meesters AA, et al. Home vs. outpatient narrowband ultraviolet B therapy for the treatment of nonsegmental vitiligo: a retrospective questionnaire study. Br J Dermatol 2010;162:1142–4. https://doi.org/10.1111/j.1365-2133.2010.09678.x doi: 10.1111/j.1365-2133.2010.09678.x. [DOI] [PubMed]
  30. Yule S, Sanyal S, Ibbotson S, Moseley H, Dawe RS. Self-administration of hospital-based narrowband ultraviolet B (TL-01) phototherapy: a feasibility study in an outpatient setting. Br J Dermatol 2013;169:464–8. https://doi.org/10.1111/bjd.12312 doi: 10.1111/bjd.12312. [DOI] [PubMed]
  31. Ibbotson SH, Bilsland D, Cox NH, Dawe RS, Diffey B, Edwards C, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004;151:283–97. https://doi.org/10.1111/j.1365-2133.2004.06128.x doi: 10.1111/j.1365-2133.2004.06128.x. [DOI] [PubMed]
  32. Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed 2012;28:115–19. https://doi.org/10.1111/j.1600-0781.2012.00648.x doi: 10.1111/j.1600-0781.2012.00648.x. [DOI] [PubMed]
  33. Eleftheriadou V, Thomas KS, Whitton ME, Batchelor JM, Ravenscroft JC. Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials. Br J Dermatol 2012;167:804–14. https://doi.org/10.1111/j.1365-2133.2012.11056.x doi: 10.1111/j.1365-2133.2012.11056.x. [DOI] [PubMed]
  34. Eleftheriadou V, Thomas K, van Geel N, Hamzavi I, Lim H, Suzuki T, et al. Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus. Pigment Cell Melanoma Res 2015;28:363–9. https://doi.org/10.1111/pcmr.12354 doi: 10.1111/pcmr.12354. [DOI] [PubMed]
  35. Eleftheriadou V, Hamzavi I, Pandya AG, Grimes P, Harris JE, Huggins RH, et al. International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. Br J Dermatol 2019;180:574–9. https://doi.org/10.1111/bjd.17013 doi: 10.1111/bjd.17013. [DOI] [PubMed]
  36. Haines RH, Thomas KS, Montgomery AA, Ravenscroft JC, Akram P, Chalmers JR, et al. Home interventions and light therapy for the treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomised controlled trial. BMJ Open 2018;8:e018649. doi: 10.1136/bmjopen-2017-018649. [DOI] [PMC free article] [PubMed]
  37. Electronic Medicines Compendium. Elocon Ointment: Summary of Product Characteristics. URL: www.medicines.org.uk/emc/product/79/smpc (accessed 7 January 2020).
  38. Hearn RM, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008;159:931–5. https://doi.org/10.1111/j.1365-2133.2008.08776.x doi: 10.1111/j.1365-2133.2008.08776.x. [DOI] [PubMed]
  39. Lin TL, Wu CY, Chang YT, Juan CK, Chen CC, Yu SH, Chen YJ. Risk of skin cancer in psoriasis patients receiving long-term narrowband ultraviolet phototherapy: results from a Taiwanese population-based cohort study. Photodermatol Photoimmunol Photomed 2019;35:164–71. https://doi.org/10.1111/phpp.12443 doi: 10.1111/phpp.12443. [DOI] [PubMed]
  40. Benzekri L, Gauthier Y, Hamada S, Hassam B. Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br J Dermatol 2013;168:265–71. https://doi.org/10.1111/bjd.12034 doi: 10.1111/bjd.12034. [DOI] [PubMed]
  41. Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D. Rook’s Textbook of Dermatology. Oxford: Wiley–Blackwell; 2016. https://doi.org/10.1002/9781118441213 doi: 10.1002/9781118441213. [DOI]
  42. Batchelor JM, Tan W, Tour S, Yong A, Montgomery AA, Thomas KS. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success. Br J Dermatol 2016;174:386–94. https://doi.org/10.1111/bjd.14208 doi: 10.1111/bjd.14208. [DOI] [PMC free article] [PubMed]
  43. Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol 2013;69:e11–8. https://doi.org/10.1016/j.jaad.2012.01.038 doi: 10.1016/j.jaad.2012.01.038. [DOI] [PubMed]
  44. Fernandez-Peñas P, Jones-Caballero M, Espallardo O, García-Díez A. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. Br J Dermatol 2012;166:884–7. https://doi.org/10.1111/j.1365-2133.2012.10806.x doi: 10.1111/j.1365-2133.2012.10806.x. [DOI] [PubMed]
  45. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res 2013;22:1717–27. https://doi.org/10.1007/s11136-012-0322-4 doi: 10.1007/s11136-012-0322-4. [DOI] [PMC free article] [PubMed]
  46. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36. https://doi.org/10.1007/s11136-011-9903-x doi: 10.1007/s11136-011-9903-x. [DOI] [PMC free article] [PubMed]
  47. Ratcliffe J, Stevens K, Flynn T, Brazier J, Sawyer MG. Whose values in health? An empirical comparison of the application of adolescent and adult values for the CHU-9D and AQOL-6D in the Australian adolescent general population. Value Health 2012;15:730–6. https://doi.org/10.1016/j.jval.2012.04.005 doi: 10.1016/j.jval.2012.04.005. [DOI] [PubMed]
  48. Thomas KS, Batchelor JM, Akram P, Chalmers JR, Haines RH, Meakin GD, et al. Randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo – results of the HI-Light Vitiligo trial [published online ahead of print October 2 2020]. Br J Dermatol 2020. https://doi.org/10.1111/bjd.19592 doi: 10.1111/bjd.19592. [DOI] [PubMed]
  49. Sach TH, Thomas KS, Batchelor JM, Akram P, Chalmers JR, Haines RH, et al. An economic evaluation of the randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo (The HI-Light Trial) [published online ahead of print September 12 2020]. Br J Dermatol 2020.
  50. McManus E, Sach T, Levell NJ. Are vitiligo treatments cost-effective? A systematic review. Br J Dermatol 2018;178:e57–e58. https://doi.org/10.1111/bjd.15881 doi: 10.1111/bjd.15881. [DOI] [PubMed]
  51. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006;55:490–500. https://doi.org/10.1016/j.jaad.2006.05.048 doi: 10.1016/j.jaad.2006.05.048. [DOI] [PubMed]
  52. Radtke MA, Schäfer I, Gajur A, Langenbruch A, Augustin M. Willingness-to-pay and quality of life in patients with vitiligo. Br J Dermatol 2009;161:134–9. https://doi.org/10.1111/j.1365-2133.2009.09091.x doi: 10.1111/j.1365-2133.2009.09091.x. [DOI] [PubMed]
  53. Drummond M SM, Claxton K, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 4th edn. Oxford: Oxford University Press; 2015.
  54. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Eff Resour Alloc 2013;11:6. https://doi.org/10.1186/1478-7547-11-6 doi: 10.1186/1478-7547-11-6. [DOI] [PMC free article] [PubMed]
  55. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II – An ISPOR Good Research Practices Task Force report. Value Health 2015;18:161–72. https://doi.org/10.1016/j.jval.2015.02.001 doi: 10.1016/j.jval.2015.02.001. [DOI] [PubMed]
  56. Glick HA DJ, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials (Handbooks in Health Economic Evaluation). 2nd edn. Oxford: Oxford University Press; 2014. https://doi.org/10.1093/med/9780199685028.001.0001 doi: 10.1093/med/9780199685028.001.0001. [DOI]
  57. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. 2013. URL: www.nice.org.uk/process/pmg9/chapter/foreword (accessed 7 January 2020). [PubMed]
  58. NHS Digital. Prescription Cost Analysis. 2017. URL: https://data.gov.uk/dataset/prescription-cost-analysis-england (accessed 7 January 2020).
  59. NHS Business Services Authority. Financial Forecasting. URL: www.nhsbsa.nhs.uk/prescription-data/understanding-our-data/financial-forecasting (accessed 3 October 2020).
  60. NHS improvement. NHS Schedule of Reference Costs 2017–2018. URL: https://improvement.nhs.uk/resources/reference-costs/ (accessed 7 January 2020).
  61. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Canterbury: PSSRU, University of Kent; 2017.
  62. NHS Digital. Prescription Cost Analysis. 2018. URL: https://data.gov.uk/dataset/prescription-cost-analysis-england (accessed 3 Febuary 2020).
  63. Stevens K. Valuation of the Child Health Utility 9D Index. PharmacoEconomics 2012;30:729–47. https://doi.org/10.2165/11599120-000000000-00000 doi: 10.2165/11599120-000000000-00000. [DOI] [PubMed]
  64. Stevens KJ, Brazier JE, McKenna SP, Doward LC, Cork MJ. The development of a preference-based measure of health in children with atopic dermatitis. Br J Dermatol 2005;153:372–7. https://doi.org/10.1111/j.1365-2133.2005.06736.x doi: 10.1111/j.1365-2133.2005.06736.x. [DOI] [PubMed]
  65. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15. https://doi.org/10.1016/j.jval.2012.02.008 doi: 10.1016/j.jval.2012.02.008. [DOI] [PubMed]
  66. National Institute for Health and Care Excellence (NICE). Position Statement on the Use of the EQ-5D-5L Valuation Set. 2018. URL: www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l (accessed 7 January 2020).
  67. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96. https://doi.org/10.1002/hec.944 doi: 10.1002/hec.944. [DOI] [PubMed]
  68. Devlin N, Shah K, Feng Y, B. M, van Hout B. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England. London: Office of Health Economics; 2016. URL: www.ohe.org/publications/valuing-health-related-quality-life-eq-5d-5l-value-set-england# (accessed 5 November 2020). doi: 10.1002/hec.3564. [DOI] [PMC free article] [PubMed]
  69. Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2018;27:7–22. https://doi.org/10.1002/hec.3564 doi: 10.1002/hec.3564. [DOI] [PMC free article] [PubMed]
  70. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32:1157–70. https://doi.org/10.1007/s40273-014-0193-3 doi: 10.1007/s40273-014-0193-3. [DOI] [PMC free article] [PubMed]
  71. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004;13:461–75. https://doi.org/10.1002/hec.843 doi: 10.1002/hec.843. [DOI] [PubMed]
  72. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 2013;13:117. https://doi.org/10.1186/1471-2288-13-117 doi: 10.1186/1471-2288-13-117. [DOI] [PMC free article] [PubMed]
  73. Ritchie J, Spencer L. Qualitative Data Analysis for Applied Policy Research. In Bryman A, Burgess R, editors. Analyzing Qualitative Data. London: Taylor & Francis; 1994. pp. 173–94. https://doi.org/10.4324/9780203413081_chapter_9 doi: 10.4324/9780203413081_chapter_9. [DOI]
  74. Tour SK, Thomas KS, Walker DM, Leighton P, Yong AS, Batchelor JM. Survey and online discussion groups to develop a patient-rated outcome measure on acceptability of treatment response in vitiligo. BMC Dermatol 2014;14:10. https://doi.org/10.1186/1471-5945-14-10 doi: 10.1186/1471-5945-14-10. [DOI] [PMC free article] [PubMed]
  75. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. Res Involv Engagem 2017;3:13. https://doi.org/10.1186/s40900-017-0062-2 doi: 10.1186/s40900-017-0062-2. [DOI] [PMC free article] [PubMed]
  76. Telford R, Boote JD, Cooper CL. What does it mean to involve consumers successfully in NHS research? A consensus study. Health Expect 2004;7:209–20. https://doi.org/10.1111/j.1369-7625.2004.00278.x doi: 10.1111/j.1369-7625.2004.00278.x. [DOI] [PMC free article] [PubMed]
  77. INVOLVE. What is Public Involvement in Research? Southampton: National Institute for Health Research. URL: www.invo.org.uk/find-out-more/what-is-public-involvement-in-research-2/ (accessed 7 January 2020).
  78. Rogers A, Akram P, Batchelor JM, Crutchley J, Grocki M, Haines RH, et al. Quality assurance and characterisation of NB-UVB devices for use at home – lessons from the Hi-Light Vitiligo trial [published online ahead of print October 27 2020]. BJD 2020. doi: 10.1111/bjd.19630. [DOI] [PMC free article] [PubMed]
  79. Koek MB, Buskens E, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Sigurdsson V. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). BMJ 2009;338:b1542. https://doi.org/10.1136/bmj.b1542 doi: 10.1136/bmj.b1542. [DOI] [PMC free article] [PubMed]
  80. Mysore V. Targeted phototherapy. Indian J Dermatol Venereol Leprol 2009;75:119–25. https://doi.org/10.4103/0378-6323.48655 doi: 10.4103/0378-6323.48655. [DOI] [PubMed]
  81. Eleftheriadou V, Ezzedine K. Portable home phototherapy for vitiligo. Clin Dermatol 2016;34:603–6. https://doi.org/10.1016/j.clindermatol.2016.05.010 doi: 10.1016/j.clindermatol.2016.05.010. [DOI] [PubMed]
  82. Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, Kim GM. Phototherapy for vitiligo: a systematic review and meta-analysis. JAMA Dermatol 2017;153:666–74. https://doi.org/10.1001/jamadermatol.2017.0002 doi: 10.1001/jamadermatol.2017.0002. [DOI] [PMC free article] [PubMed]
  83. Lim-Ong M, Leveriza R, Ong B, M. F. Comparison between narrow-band UVB with topical corticosteroid and narrow-band UVB with placebo in the treatment of vitiligo: a randomized controlled trial. J Phillipine Dermatol Soc 2005;14:17–22.
  84. Momen S, Sarkany R. Are very high cumulative doses of narrowband UVB safe in vitiligo? Photodermatol Photoimmunol Photomed 2017;33:220–1. https://doi.org/10.1111/phpp.12306 doi: 10.1111/phpp.12306. [DOI] [PubMed]
  85. Arora CJ, Rafiq M, Shumack S, Gupta M. The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo: a systematic review of randomised clinical trials. Australas J Dermatol 2020;61:e1–e9. https://doi.org/10.1111/ajd.13096 doi: 10.1111/ajd.13096. [DOI] [PubMed]
  86. Talsania N, Lamb B, Bewley A. Vitiligo is more than skin deep: a survey of members of The Vitiligo Society. Clin Exp Dermatol 2010;35:736–9. https://doi.org/10.1111/j.1365-2230.2009.03765.x doi: 10.1111/j.1365-2230.2009.03765.x. [DOI] [PubMed]
  87. Teasdale E, Muller I, Abdullah Sani A, Thomas KS, Stuart B, Santer M. Views and experiences of seeking information and help for vitiligo: a qualitative study of written accounts. BMJ Open 2018;8:e018652. https://doi.org/10.1136/bmjopen-2017-018652 doi: 10.1136/bmjopen-2017-018652. [DOI] [PMC free article] [PubMed]
  88. National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summaries (CKS) Vitiligo – Scenario: Management of Vitiligo. 2016. URL: https://cks.nice.org.uk/vitiligo#!scenarioRecommendation:2 (accessed 7 January 2020).

RESOURCES